IHS Chemical Week

EnviroTech :: Innovation

Lonza to Supply Commercial Volumes of Antibody Drug

4:46 AM MST | November 10, 2009 | Alex Scott

Lonza has disclosed that GlaxoSmithKline (GSK) and Genmab’s antibody drug Arzerra, for treating chronic lymphocytic leukemia (CLL), will be manufactured by Lonza. Arzerra, also known as ofatumumab, is a monoclonal antibody. The drug recently has been approved by the U.S. FDA. Lonza carried out process development and cGMP manufacturing services associated with the production of the drug. Lonza says it will supply the drug under the terms of a long-term supply agreement. Financial details were not disclosed.   Some analysts suggest sales of the drug for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa